Random forest classifiers aid in the detection of incidental osteoblastic osseous metastases in DEXA studies
- 40 Downloads
Dual-energy X-ray absorptiometry (DEXA) studies are used for screening patients for low bone mineral density (BMD). Patients with breast and prostate cancer are often treated with hormone-altering drugs that result in low BMD. These patients may have incidental osteoblastic metastases of the spine that may be detected on screening DEXA studies. The aim of this pilot study is to assess whether random forest classifiers or support vector machines can identify patients with incidental osteoblastic metastases of the spine from screening DEXA studies and to evaluate which technique is better.
We retrospectively reviewed the DEXA studies from 200 patients (155 normal control patients and 45 patients with osteoblastic metastases of one or more lumbar vertebral bodies from L1 to L4). The dataset was split into training (80%) and validation (20%) datasets. The optimal random forest (RF) and support vector machine (SVM) classifiers were obtained. Receiver-operator-characteristic curves were compared with DeLong’s test.
The sensitivity, specificity, accuracy and area under the curve (AUC) of the optimal RF classifier were 77.8%, 100.0%, 98.0% and 0.889, respectively, in the validation dataset. The sensitivity, specificity, accuracy and AUC of the optimal SVM classifier were 33.3%, 96.8%, 82.5% and 0.651 in the validation dataset. The RF classifier was significantly better than the SVM classifier (P = 0.008). Only 7 of the 45 patients with osteoblastic metastases (15.6%) were prospectively identified by the radiologist interpreting the study.
RF classifiers can be used as a useful adjunct to identify incidental lumbar spine osteoblastic metastases in screening DEXA studies.
KeywordsRandom forest Support vector machine DEXA, machine learning Artificial intelligence
RS was funded by a Radiology Society of North America Research Grant.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Human and animal rights statement
All human studies have been approved and performed in accordance with ethical standards.
The study was reviewed and approved by the senior author’s Institutional Review Board, and the need for signed informed consent from each participant was waived.
- 3.Qaseem A, Forciea MA, McLean RM, Denberg TD, Clinical Guidelines Committee of the American College of Physicians (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166(11):818–839CrossRefGoogle Scholar
- 8.WHO Scientific Group on the Prevention and Management of Osteoporosis (2000: Geneva, Switzerland) (2003). Prevention and management of osteoporosis: report of a WHO scientific groupGoogle Scholar
- 9.Mazess RB, Barden HS (1988) Measurement of bone by dual-photon absorptiometry (DPA) and dual-energy X-ray absorptiometry (DEXA). Ann Chir Gynaecol 77(5–6):197–203Google Scholar
- 13.Kanis JA on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. University of Sheffield, UK World Health Organization Collaborating Centre for Metabolic Bone Diseases. University of Sheffield, 2007Google Scholar
- 14.Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29(11):2520–2526. https://doi.org/10.1002/jbmr.2269 CrossRefGoogle Scholar
- 15.Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists group (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21(8):1215–1223CrossRefGoogle Scholar
- 17.Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S, American Society of Clinical Oncology (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21(21):4042–4057 Epub 2003 Sep 8 CrossRefGoogle Scholar
- 20.National Institute for Health and Clinical Excellence (2018) Early and locally advanced breast cancer: Diagnosis and treatment (NG101)Google Scholar
- 27.Ben-Hur A, Horn D, Siegelmann H, Vapnik V (2001) Support vector clustering. J Mach Learn Res 2:125–137Google Scholar